Alnylam Pharmaceuticals ALNY Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's other income (expense)?
- Alnylam Pharmaceuticals (ALNY) reported other income (expense) of -$53.64M in Q2 2026.
- How has Alnylam Pharmaceuticals's other income (expense) changed year-over-year?
- Alnylam Pharmaceuticals's other income (expense) decreased by 179.9% year-over-year, from -$19.16M to -$53.64M.
- What is the long-term trend for Alnylam Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's other income (expense) has grown at a 10.5% compound annual growth rate (CAGR), from -$143.49M to -$214.07M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.